7 Stocks to Sell Now

In This Article:

In 2022, the stock market has faced a plethora of negative factors, from the Russian invasion of Ukraine and the soaring energy prices that followed to the historic high inflation, the shift in the monetary policy by the Federal Reserve and now the danger of a recession. Given all this, in addition to finding good stocks to buy, you need to be culling your portfolio of stocks to sell.

The major stock indexes are all in red and investment strategies that favor selling stocks in a weak or bear market has paid off year-to-date.

Selling the following stocks makes sense for any investor analyzing current market conditions. Do not fight the major downtrend — sell stocks with weak fundamentals. It may sound simple, but simplicity is often the best way to participate in stock market movements.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

So let’s look at these stocks to sell now, before they punish investors further.

NPTN

NeoPhotonics

$15.73

RVLP

RVL Pharmaceuticals

$1.31

WOLF

Wolfspeed

$74.75

TRIP

TripAdvisor

$18.10

GSIT

GSI Technology

$3.84

CLNE

Clean Energy Fuels

$5.05

DBRG

DigitalBridge Group

$4.93

NeoPhotonics (NPTN)

A photo of a purple and green laser going through an object
A photo of a purple and green laser going through an object

Source: science photo / ShutterStock.com

NeoPhotonics (NYSE:NPTN), the first of my stocks to sell, “is a leading developer and manufacturer of ultra-pure light lasers and optoelectronic products that transmit, receive and switch the highest speed over distance digital optical signals for Cloud and hyper-scale data center internet content provider and telecom networks.”

The stock is up nearly 81% in the past year and about 3% year-to-date. Meanwhile, the firm has had a slowing sales growth trend in the past two years, and in 2021 the revenue growth turned negative at -21.79%.

Its negative net income for the past five years also shouldn’t give you confidence in its business prospects and performance. In 2021 net losses widened to -$40.72 million from -$4.37 million in 2020. The stock is pricey trading at a price/book ratio of 5.56.

The shareholders have also been diluted in the past year, with total shares outstanding growing by 4.2%. All this adds up to a stock to sell until it shapes up.

RVL Pharmaceuticals (RVLP)

two doctors look over a piece of paper while standing in a hallway
two doctors look over a piece of paper while standing in a hallway

Source: Shutterstock

RVL Pharmaceuticals (NASDAQ:RVLP) “is a specialty pharmaceutical company focused on developing and commercializing eyecare and medical aesthetics products.”

The shares have gains of about 23% in 2022 which is astonishing after analyzing the fundamentals of the firm.

Sales growth not only slowed over the past three consecutive years, but it actually turned negative — in 2019, 2020 and 2021 the firm reported a sales growth of -8.98%, -88.43% and-36.96% respectively. The profitability simply does not exist.